Please try another search
CHO Pharma, Inc., a biopharmaceutical company, develops and commercializes therapeutic and diagnostic products for the unmet clinical needs. It is developing homogeneous antibody drugs, such as CHO-H01, CHO-H02, and CHO-A04, a humanized monoclonal antibody for cancer; CHO-H03, a homogeneous antibody drug for autoimmune diseases; CHO-S05 dual-effect anti-flu drugs; and CHO-V08 for Klebsiella pneumonia. The company was founded in 2012 and is based in Taipei City, Taiwan.
Name | Age | Since | Title |
---|---|---|---|
Chinh-Yi Wu | - | 2022 | GM & Board Member |
Ming-Hsing Tsai | 66 | 2022 | Director |
Chao-Long Chen | - | - | Chairman |
Shaw T. Chen | - | - | Member of Scientific Advisory Board |
Chi-Huey Wong | - | - | Chairman of Scientific Advisory Board |
Hsieng S. Lu | - | - | Member of Scientific Advisory Board |
Shuan-Ta Liu | - | 2019 | Independent Director |
Kuo-I Lin | - | 2021 | Member of Scientific Advisory Board |
Che Alex Ma | - | - | Member of Scientific Advisory Board |
Pan-Chyr Yang | - | - | Member of Scientific Advisory Board |
Chung-Yi Wu | - | 2022 | President, CEO, GM & Director |
Yun-Ching Yeh | - | 2022 | Board Member |
Victor Ma | - | 2022 | Board Member |
Mei-Shang Ho | - | 2021 | Member of Scientific Advisory Board |
Hong-Nerng Ho | - | - | Independent Director |
Chung-Liang Chien | - | - | Independent Director |
Shun-Ling Chen | - | 2022 | Board Member |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review